C72.40: Malignant neoplasm of unspecified acoustic nerve
C72.40, malignant neoplasm of unspecified acoustic nerve, is listed as a covered diagnosis in 4 Medicare billing and coding articles that apply to 21 HCPCS Level II codes, including G0340 (Image-guided robotic linear accelerator-based stereotactic…), G0339 (Image-guided robotic linear accelerator-based stereotactic…), G0563 (Stereotactic body radiation therapy, treatment delivery…). The articles come from 3 Medicare contractors. A listed diagnosis supports medical necessity only; coverage still depends on the LCD's criteria and on documentation in the medical record.
HCPCS Level II codes with C72.40 as a covered diagnosis
| Code | Description | Medicare coverage | DMEPOS fee 2026 (state range) | Articles listing it |
|---|---|---|---|---|
| G0340 | Image-guided robotic linear accelerator-based stereotactic radiosurgery, delivery including collimator changes and custom plugging, fractionated treatment, all lesions, per session, second through fifth sessions, maximum five sessions per course of treatment | Carrier judgment | — | 1 |
| G0339 | Image-guided robotic linear accelerator-based stereotactic radiosurgery, complete course of therapy in one session or first session of fractionated treatment | Carrier judgment | — | 1 |
| G0563 | Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance and real-time positron emissions-based delivery adjustments to 1 or more lesions, entire course not to exceed 5 fractions | Carrier judgment | — | 1 |
| G0453 | Continuous intraoperative neurophysiology monitoring, from outside the operating room (remote or nearby), per patient, (attention directed exclusively to one patient) each 15 minutes (list in addition to primary procedure) | Carrier judgment | — | 1 |
| Q5110 | Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | Special coverage instructions apply | — | 1 |
| Q5125 | Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram | Carrier judgment | — | 1 |
| Q5101 | Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | Special coverage instructions apply | — | 1 |
| J1442 | Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | Special coverage instructions apply | — | 1 |
| J1449 | Injection, eflapegrastim-xnst, 0.1 mg | Carrier judgment | — | 1 |
| J1447 | Injection, tbo-filgrastim, 1 microgram | Special coverage instructions apply | — | 1 |
| Q5108 | Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | Carrier judgment | — | 1 |
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | Carrier judgment | — | 1 |
| Q5127 | Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg | Carrier judgment | — | 1 |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Carrier judgment | — | 1 |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | Carrier judgment | — | 1 |
| Q5130 | Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg | Carrier judgment | — | 1 |
| J2820 | Injection, sargramostim (gm-csf), 50 mcg | Special coverage instructions apply | — | 1 |
| Q5120 | Injection, pegfilgrastim-bmez (ziextenzo), biosimilar, 0.5 mg | Carrier judgment | — | 1 |
| Q5148 | Injection, filgrastim-txid (nypozi), biosimilar, 1 microgram | Special coverage instructions apply | — | 1 |
| Q5169 | Injection, pegfilgrastim-unne (armlupeg), biosimilar, 0.5 mg | Carrier judgment | — | 1 |
| G0255 | Current perception threshold/sensory nerve conduction test, (snct) per limb, any nerve | Non-covered by Medicare | Not covered | 1 |
Medicare policy articles listing C72.40
- A56874: Billing and Coding: Stereotactic Radiation Therapy: Stereotactic Radiosurgery (SRS) and Stereotactic Body Radiation Therapy (SBRT) (Wellpoint Federal (MAC - Part A, MAC - Part B); 3 Level II codes). LCD with the same title: L35076
- A56722: Billing and Coding: Intraoperative Neurophysiological Testing (Novitas Solutions, Inc. (MAC - Part A, MAC - Part B); 1 Level II codes). LCD with the same title: L34623, L35003
- A56748: Billing and Coding: White Cell Colony Stimulating Factors (Palmetto GBA (MAC - Part A, MAC - Part B); 16 Level II codes). LCD with the same title: L37176
- A57668: Billing and Coding: Nerve Conduction Studies and Electromyography (Wellpoint Federal (MAC - Part A, MAC - Part B); 1 Level II codes). LCD with the same title: L34594, L34859, L35048, L35081
A diagnosis listed as covered in a billing and coding article supports medical necessity for the article's codes; it does not guarantee payment. Coverage depends on the LCD's criteria, the contractor's jurisdiction and documentation in the medical record.
Other C72 diagnoses (Malignant neoplasm of spinal cord, cranial nerves and other parts of central nervous system)
- C72.41 — Malignant neoplasm of right acoustic nerve
- C72.42 — Malignant neoplasm of left acoustic nerve
- C72.0 — Malignant neoplasm of spinal cord
- C72.1 — Malignant neoplasm of cauda equina
- C72.20 — Malignant neoplasm of unspecified olfactory nerve
- C72.21 — Malignant neoplasm of right olfactory nerve
- C72.22 — Malignant neoplasm of left olfactory nerve
- C72.30 — Malignant neoplasm of unspecified optic nerve
- C72.31 — Malignant neoplasm of right optic nerve
- C72.32 — Malignant neoplasm of left optic nerve
- C72.50 — Malignant neoplasm of unspecified cranial nerve
- C72.59 — Malignant neoplasm of other cranial nerves
- C72.9 — Malignant neoplasm of central nervous system, unspecified
Frequently asked questions
Does Medicare cover C72.40 (Malignant neoplasm of unspecified acoustic nerve)?
Medicare covers items and services, not diagnoses. 4 Medicare billing and coding articles list C72.40 as a covered diagnosis for 21 HCPCS Level II codes: the diagnosis can support medical necessity for those codes, but payment still depends on the LCD's coverage criteria and the medical record.
Which HCPCS codes can be billed with ICD-10 C72.40?
The Level II codes from the policies most specific to this diagnosis are G0340 (Image-guided robotic linear accelerator-based stereotactic…, 1 article); G0339 (Image-guided robotic linear accelerator-based stereotactic…, 1 article); G0563 (Stereotactic body radiation therapy, treatment delivery…, 1 article); G0453 (Continuous intraoperative neurophysiology monitoring, from…, 1 article); Q5110 (Injection, filgrastim-aafi, biosimilar, (nivestym), 1…, 1 article). Code choice depends on the item supplied; check each code's descriptor.
Which Medicare policy articles list C72.40?
A56874 (Billing and Coding: Stereotactic Radiation Therapy: Stereotactic Radiosurgery (SRS) and Stereotactic Body Radiation Therapy (SBRT)); A56722 (Billing and Coding: Intraoperative Neurophysiological Testing); A56748 (Billing and Coding: White Cell Colony Stimulating Factors), and 1 more article.
What is ICD-10-CM code C72.40?
C72.40 is the ICD-10-CM code for malignant neoplasm of unspecified acoustic nerve, in category C72 (Malignant neoplasm of spinal cord, cranial nerves and other parts of central nervous system), chapter 2: Neoplasms.
Next steps
- Run a reimbursement report for a device billed under G0340
- Watch G0340 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for G0340
Sources: CMS Medicare Coverage Database billing and coding articles (covered ICD-10 code lists and HCPCS links); ICD-10-CM FY2026; CMS HCPCS Level II release October 2026; CMS DMEPOS fee schedule 2026 (non-rural state fees). Not billing or legal advice.